ArticleCureus2025
A Rare Case of Mixed Malignant Ovarian Germ Cell Tumor Composed of Immature Teratoma and Yolk Sac Tumor.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant ovarian germ cell tumors (MOGCTs) are rare but aggressive neoplasms, accounting for a small percentage of ovarian cancers, and often affect young women. We present the case of a 23-year-old woman who presented to the clinic believing she was 14.2 weeks pregnant. However, she was found to have elevated beta-human chorionic gonadotropin (β-hCG) levels and a complex left adnexal mass. Initial ultrasound suggested an ovarian tumor, and surgical exploration revealed a large mixed germ cell tumor measuring 36.5 x 27 x 23.9 cm, weighing 9463.2 grams, with metastases to the small bowel, omentum, and peritoneum. Final pathology confirmed a high-grade immature teratoma and yolk sac tumor with a composition of 60% teratoma and 40% yolk sac tumor (YST). The patient underwent comprehensive staging surgery, including omentectomy, bowel resection, and lymphadenectomy, followed by four cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy. Unfortunately, the patient has not responded to the standard chemotherapy regimen of BEP and will pursue further treatment through clinical trials. This case highlights the diagnostic challenge of MOGCTs, particularly mixed forms, which may present with nonspecific symptoms. Timely diagnosis and aggressive treatment, including fertility-preserving surgery when possible, are crucial for improving outcomes. Although survival rates are generally favorable, close follow-up is needed due to the potential for relapse, particularly in cases with advanced disease, as seen in our case. This case emphasizes the importance of considering MOGCTs in young women with elevated β-hCG and adnexal masses and the management of this metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.